Astral Codex Ten

Luvox

4 min read

Luvox

Article

Luvox is a recurring brand in the Astral Codex Ten archive, appearing 2 times across 2 issues between December 22, 2021 and December 22, 2021. The archive places it in contexts such as “get the FDA to approve Luvox for COVID”; “Here’s my pitch for fluvoxamine (Luvox) for COVID”; “the risk from adding a few extra Luvox prescriptions for COVID is still much less”. It most often appears alongside budesonide, FDA, fluvoxamine.

Metadata

  • Category: Brands
  • Mention count: 2
  • Issue count: 2
  • First seen: December 22, 2021
  • Last seen: December 22, 2021

Appears In

Source Context

Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.

The FDA Has Punted Decisions About Luvox Prescription To The Deepest Recesses Of The Human Soul
December 22, 2021 · Original source
Here’s my pitch for fluvoxamine (Luvox) for COVID.
But a different drug, the SSRI antidepressant fluvoxamine, actually did really well! It decreased COVID hospitalizations by about 30% - not the perfect cure rate the rumors attributed to ivermectin, but a substantial decrease. Given the size and professionalism of this study, and another smaller one that also got positive results, I and many others take Luvox pretty seriously. At this point I’d give it 60-40 it works.
What are the risks? Like every medication, including Tylenol, aspirin, etc, Luvox has some common minor side effects and some rare major ones. But let’s step back a second. Fluvoxamine is a bog-standard SSRI. Its side effects are generic SSRI side effects. We give SSRIs to 30 million people a year, or about 10% of all Americans. As a psychiatrist, I’m not supposed to say flippant things like “we give SSRIs out like candy”. We do careful risk-benefit analysis and when appropriate we screen patients for various risk factors. But after we do all that stuff, we give them to 10% of Americans, compared to 12% of Americans who got candy last Halloween. So you can draw your own conclusion about how severe we think the risks are.
Inline links: 12% of Americans
Addendum To Luvox Post
December 22, 2021 · Original source
In my post yesterday, I quoted a Vox article describing work by Dr. Ed Mills and others to get the FDA to approve Luvox for COVID. As of that point, the FDA didn’t know how to process an application without a sponsoring drug company:
Inline links: quoted a Vox
[Professor Ed] Mills, who thinks that fluvoxamine and budesonide are both appropriate to prescribe to patients sick with Covid-19, compares public messaging on fluvoxamine to communications about Merck’s drug molnupiravir. The evidence for molnupiravir is in many ways weaker than the evidence for fluvoxamine, but molnupiravir was produced by a major pharmaceutical company that can shepherd it through the process of becoming a recommended drug. On a call last week, Mills said, the FDA told him “they don’t know how to deal with submissions where there isn’t someone to be responsible for it.”
But it looks like just as I published, he and his colleagues found a way around the problem: #IDTwitter we submitted EUA Application for #Fluvoxamine for #COVID19 to @US_FDA with the assistance of @EricLenze2 @AngelaReiersen @drklausner @ShohamTxID, and Ed Mills \nIf you want to sign a letter of support forms.gle/3mDgxxgMgtVDNS…\n(names are not public & will be reviewed) ","username":"boulware_dr","name":"David Boulware, MD MPH","profile_image_url":"","date":"Tue Dec 21 21:14:24 +0000 2021","photos":[],"quoted_tweet":{"full_text":"#IDTwitter For those in the medical community who would want to sign on to a letter of support for @US_FDA EUA Application for #Fluvoxamine please go here: https://t.co/7K0OCSSm3O \n\n(I ask others to not spam this, as this creates more work for me in reviewing the list).","username":"boulware_dr","name":"David Boulware, MD MPH"},"reply_count":0,"retweet_count":36,"like_count":122,"impression_count":0,"expanded_url":{},"video_url":null,"belowTheFold":false}" data-component-name="Twitter2ToDOM"> …though so far I’m having trouble figuring out their exact strategy: